GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » EPS without NRI

Lantern Pharma (Lantern Pharma) EPS without NRI : $-1.63 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma EPS without NRI?

Lantern Pharma's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.51. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.63.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Lantern Pharma's EPS without NRI or its related term are showing as below:

LTRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.6   Med: -49.6   Max: -2.4
Current: -2.4

During the past 6 years, Lantern Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -2.40% per year. The lowest was -59.60% per year. And the median was -49.60% per year.

LTRN's 3-Year EPS without NRI Growth Rate is ranked worse than
59.35% of 1299 companies
in the Biotechnology industry
Industry Median: 5.2 vs LTRN: -2.40

Lantern Pharma's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.51. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.63.

Lantern Pharma's EPS (Basic) for the three months ended in Mar. 2024 was $-0.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.63.


Lantern Pharma EPS without NRI Historical Data

The historical data trend for Lantern Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma EPS without NRI Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.39 -1.37 -1.13 -1.31 -1.47

Lantern Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.44 -0.29 -0.39 -0.51

Competitive Comparison of Lantern Pharma's EPS without NRI

For the Biotechnology subindustry, Lantern Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantern Pharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's PE Ratio without NRI falls into.



Lantern Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantern Pharma  (NAS:LTRN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lantern Pharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantern Pharma (Lantern Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini director 1223 FOXGLOVE LANE, WEST CHESTER PA 19380

Lantern Pharma (Lantern Pharma) Headlines

From GuruFocus